Published in Am J Pathol on February 01, 1994
The cancer paradigm of severe pulmonary arterial hypertension. Am J Respir Crit Care Med (2008) 3.09
Modern age pathology of pulmonary arterial hypertension. Am J Respir Crit Care Med (2012) 2.68
Interleukin-6 overexpression induces pulmonary hypertension. Circ Res (2008) 2.64
Monoclonal endothelial cell proliferation is present in primary but not secondary pulmonary hypertension. J Clin Invest (1998) 2.54
Alterations of cellular bioenergetics in pulmonary artery endothelial cells. Proc Natl Acad Sci U S A (2007) 2.44
Pathology of pulmonary hypertension. Clin Chest Med (2007) 2.34
Increased gene expression for VEGF and the VEGF receptors KDR/Flk and Flt in lungs exposed to acute or to chronic hypoxia. Modulation of gene expression by nitric oxide. J Clin Invest (1995) 2.30
Targeted expression of heme oxygenase-1 prevents the pulmonary inflammatory and vascular responses to hypoxia. Proc Natl Acad Sci U S A (2001) 2.21
Somatic chromosome abnormalities in the lungs of patients with pulmonary arterial hypertension. Am J Respir Crit Care Med (2010) 2.09
Pulmonary arterial remodeling induced by a Th2 immune response. J Exp Med (2008) 2.08
Endothelial-myofibroblast transition contributes to the early development of diabetic renal interstitial fibrosis in streptozotocin-induced diabetic mice. Am J Pathol (2009) 2.01
Enhanced bronchial expression of vascular endothelial growth factor and receptors (Flk-1 and Flt-1) in patients with chronic obstructive pulmonary disease. Thorax (2005) 1.99
Relevant issues in the pathology and pathobiology of pulmonary hypertension. J Am Coll Cardiol (2013) 1.96
Circulating angiogenic precursors in idiopathic pulmonary arterial hypertension. Am J Pathol (2008) 1.90
Hypoxia inducible-factor1alpha regulates the metabolic shift of pulmonary hypertensive endothelial cells. Am J Pathol (2010) 1.79
Increased regulatory and decreased CD8+ cytotoxic T cells in the blood of patients with idiopathic pulmonary arterial hypertension. Respiration (2007) 1.67
Three-dimensional reconstruction of pulmonary arteries in plexiform pulmonary hypertension using cell-specific markers. Evidence for a dynamic and heterogeneous process of pulmonary endothelial cell growth. Am J Pathol (1999) 1.63
Evidence of dysfunction of endothelial progenitors in pulmonary arterial hypertension. Am J Respir Crit Care Med (2009) 1.58
Altered immune phenotype in peripheral blood cells of patients with scleroderma-associated pulmonary hypertension. Clin Transl Sci (2010) 1.56
Adiponectin deficiency: a model of pulmonary hypertension associated with pulmonary vascular disease. Am J Physiol Lung Cell Mol Physiol (2009) 1.51
Nitric oxide, oxidative stress and inflammation in pulmonary arterial hypertension. J Hypertens (2010) 1.43
Absence of T cells confers increased pulmonary arterial hypertension and vascular remodeling. Am J Respir Crit Care Med (2007) 1.42
Targeting energetic metabolism: a new frontier in the pathogenesis and treatment of pulmonary hypertension. Am J Respir Crit Care Med (2011) 1.41
Pathobiology of pulmonary arterial hypertension and right ventricular failure. Eur Respir J (2012) 1.39
Inflammation and immunity in the pathogenesis of pulmonary arterial hypertension. Circ Res (2014) 1.38
Endothelial cells and pulmonary arterial hypertension: apoptosis, proliferation, interaction and transdifferentiation. Respir Res (2009) 1.35
High levels of hyaluronan in idiopathic pulmonary arterial hypertension. Am J Physiol Lung Cell Mol Physiol (2008) 1.34
Early macrophage recruitment and alternative activation are critical for the later development of hypoxia-induced pulmonary hypertension. Circulation (2011) 1.34
Reversible or irreversible remodeling in pulmonary arterial hypertension. Am J Respir Cell Mol Biol (2009) 1.33
Inhibition of 5-lipoxygenase-activating protein (FLAP) reduces pulmonary vascular reactivity and pulmonary hypertension in hypoxic rats. J Clin Invest (1996) 1.25
Human primary lung endothelial cells in culture. Am J Respir Cell Mol Biol (2012) 1.24
New mechanisms of pulmonary arterial hypertension: role of Ca²⁺ signaling. Am J Physiol Heart Circ Physiol (2012) 1.24
Plexiform lesions in pulmonary arterial hypertension composition, architecture, and microenvironment. Am J Pathol (2011) 1.23
Long-term effects of epoprostenol on the pulmonary vasculature in idiopathic pulmonary arterial hypertension. Chest (2010) 1.22
Pulmonary hypertension: diagnosis and management. Mayo Clin Proc (2009) 1.18
Soluble adhesion molecules (sVCAM-1, sE-selectin), vascular endothelial growth factor (VEGF) and endothelin-1 in patients with systemic sclerosis: relationship to organ systemic involvement. Clin Rheumatol (2004) 1.16
IL-32-dependent effects of IL-1beta on endothelial cell functions. Proc Natl Acad Sci U S A (2009) 1.14
Inhibition of MRP4 prevents and reverses pulmonary hypertension in mice. J Clin Invest (2011) 1.13
Pulmonary arterial hypertension: the clinical syndrome. Circ Res (2014) 1.11
Acute vasodilator effects of inhaled fasudil, a specific Rho-kinase inhibitor, in patients with pulmonary arterial hypertension. Heart Vessels (2010) 1.10
Idiopathic pulmonary arterial hypertension. Dis Model Mech (2010) 1.09
New trial designs and potential therapies for pulmonary artery hypertension. J Am Coll Cardiol (2013) 1.08
From form to function: the role of Nox4 in the cardiovascular system. Front Physiol (2012) 1.07
Role of serotonin in the pathogenesis of acute and chronic pulmonary hypertension. Thorax (1999) 1.07
Genetics and mediators in pulmonary arterial hypertension. Clin Chest Med (2007) 1.06
Reactive oxygen species in pulmonary vascular remodeling. Compr Physiol (2013) 1.06
Pulmonary hypertension can be a sequela of prior Pneumocystis pneumonia. Am J Pathol (2007) 1.05
Identification of a lysosomal pathway regulating degradation of the bone morphogenetic protein receptor type II. J Biol Chem (2010) 1.05
Development of occlusive neointimal lesions in distal pulmonary arteries of endothelin B receptor-deficient rats: a new model of severe pulmonary arterial hypertension. Circulation (2005) 1.04
STAT3 signaling in pulmonary arterial hypertension. JAKSTAT (2012) 1.04
Immune and inflammatory mechanisms in pulmonary arterial hypertension. Prog Cardiovasc Dis (2012) 1.03
How valid are animal models to evaluate treatments for pulmonary hypertension? Naunyn Schmiedebergs Arch Pharmacol (2006) 1.03
Hypoxia-inducible factor-1 α/platelet derived growth factor axis in HIV-associated pulmonary vascular remodeling. Respir Res (2011) 1.03
Systemic sclerosis-associated pulmonary arterial hypertension. Am J Respir Crit Care Med (2010) 1.03
Angiogenesis in chronic lung disease. Chest (2007) 1.03
The immune system in hypertension. Adv Physiol Educ (2014) 1.03
Metabolic dysfunction in pulmonary hypertension: the expanding relevance of the Warburg effect. Eur J Clin Invest (2013) 1.03
Effect of PPARgamma inhibition on pulmonary endothelial cell gene expression: gene profiling in pulmonary hypertension. Physiol Genomics (2009) 1.02
High mobility group box 1 contributes to the pathogenesis of experimental pulmonary hypertension via activation of Toll-like receptor 4. Mol Med (2013) 1.02
Reduced BMPR2 expression induces GM-CSF translation and macrophage recruitment in humans and mice to exacerbate pulmonary hypertension. J Exp Med (2014) 1.01
Mineralocorticoid receptor antagonism attenuates experimental pulmonary hypertension. Am J Physiol Lung Cell Mol Physiol (2013) 0.99
Vascular endothelial growth factor as a non-invasive marker of pulmonary vascular remodeling in patients with bronchitis-type of COPD. Respir Res (2007) 0.99
Lipopolysaccharide and interleukin 1 augment the effects of hypoxia and inflammation in human pulmonary arterial tissue. Proc Natl Acad Sci U S A (1996) 0.98
The crossroads of iron with hypoxia and cellular metabolism. Implications in the pathobiology of pulmonary hypertension. Am J Respir Cell Mol Biol (2014) 0.98
IL-32 promotes angiogenesis. J Immunol (2013) 0.98
Nongenomic STAT5-dependent effects on Golgi apparatus and endoplasmic reticulum structure and function. Am J Physiol Cell Physiol (2011) 0.98
T lymphocyte subset abnormalities in the blood and lung in pulmonary arterial hypertension. Respir Med (2009) 0.98
GDF-15 is abundantly expressed in plexiform lesions in patients with pulmonary arterial hypertension and affects proliferation and apoptosis of pulmonary endothelial cells. Respir Res (2011) 0.97
Obesity and pulmonary arterial hypertension: Is adiponectin the molecular link between these conditions? Pulm Circ (2012) 0.96
RhoA/Rho-kinase signaling: a therapeutic target in pulmonary hypertension. Vasc Health Risk Manag (2009) 0.96
Pyrrolidine dithiocarbamate restores endothelial cell membrane integrity and attenuates monocrotaline-induced pulmonary artery hypertension. Am J Physiol Lung Cell Mol Physiol (2008) 0.95
Signal transduction in the development of pulmonary arterial hypertension. Pulm Circ (2013) 0.95
Increased oxidative stress and severe arterial remodeling induced by permanent high-flow challenge in experimental pulmonary hypertension. Respir Res (2011) 0.95
Pulmonary hypertension in a patient with adult-onset Stills disease. Clin Rheumatol (2006) 0.94
Extracellular matrix synthesis in vascular disease: hypertension, and atherosclerosis. J Biomed Res (2013) 0.93
Copper dependence of angioproliferation in pulmonary arterial hypertension in rats and humans. Am J Respir Cell Mol Biol (2011) 0.93
Bosentan inhibits oxidative and nitrosative stress and rescues occlusive pulmonary hypertension. Free Radic Biol Med (2012) 0.93
Peptide-directed highly selective targeting of pulmonary arterial hypertension. Am J Pathol (2011) 0.93
Pulmonary hypertension associated with HIV infection: pulmonary vascular disease: the global perspective. Chest (2010) 0.93
Role of the CX3CL1-CX3CR1 axis in chronic inflammatory lung diseases. Int J Clin Exp Med (2010) 0.93
Attenuation of leukocyte recruitment via CXCR1/2 inhibition stops the progression of PAH in mice with genetic ablation of endothelial BMPR-II. Blood (2011) 0.92
Nuclear factor κ-B is activated in the pulmonary vessels of patients with end-stage idiopathic pulmonary arterial hypertension. PLoS One (2013) 0.91
Neutrophil elastase is produced by pulmonary artery smooth muscle cells and is linked to neointimal lesions. Am J Pathol (2011) 0.91
Human Immunodeficiency Virus nef signature sequences are associated with pulmonary hypertension. AIDS Res Hum Retroviruses (2012) 0.91
Deletion of ADORA2B from myeloid cells dampens lung fibrosis and pulmonary hypertension. FASEB J (2014) 0.91
Interleukin-6/interleukin-21 signaling axis is critical in the pathogenesis of pulmonary arterial hypertension. Proc Natl Acad Sci U S A (2015) 0.90
Anticipated classes of new medications and molecular targets for pulmonary arterial hypertension. Pulm Circ (2013) 0.90
Adiponectin decreases pulmonary arterial remodeling in murine models of pulmonary hypertension. Am J Respir Cell Mol Biol (2010) 0.90
Recent progress in understanding pediatric pulmonary hypertension. Curr Opin Pediatr (2011) 0.89
BMPR2 mutation alters the lung macrophage endothelin-1 cascade in a mouse model and patients with heritable pulmonary artery hypertension. Am J Physiol Lung Cell Mol Physiol (2010) 0.89
AAV delivery of tumor necrosis factor-α short hairpin RNA attenuates cold-induced pulmonary hypertension and pulmonary arterial remodeling. Hypertension (2014) 0.88
Hypoxia does neither stimulate pulmonary artery endothelial cell proliferation in mice and rats with pulmonary hypertension and vascular remodeling nor in human pulmonary artery endothelial cells. J Vasc Res (2011) 0.88
[Medicinal vasoactive therapy of microcirculation disorders in rheumatoid arthritis]. Z Rheumatol (2005) 0.88
Gene delivery of cytochrome p450 epoxygenase ameliorates monocrotaline-induced pulmonary artery hypertension in rats. Am J Respir Cell Mol Biol (2010) 0.87
Plexiform lesion in severe pulmonary hypertension: association with glomeruloid lesion. Am J Pathol (2001) 0.87
Adenosine A1 receptors promote vasa vasorum endothelial cell barrier integrity via Gi and Akt-dependent actin cytoskeleton remodeling. PLoS One (2013) 0.87
PPARgamma as a potential therapeutic target in pulmonary hypertension. Ther Adv Respir Dis (2010) 0.87
Restoration of impaired endothelial myocyte enhancer factor 2 function rescues pulmonary arterial hypertension. Circulation (2014) 0.86
High-mobility group box-1 induces vascular remodelling processes via c-Jun activation. J Cell Mol Med (2015) 0.86
Prognostic Significance of Biomarkers in Pulmonary Arterial Hypertension. Ann Am Thorac Soc (2016) 0.85
The pathogenesis of atherosclerosis: a perspective for the 1990s. Nature (1993) 27.07
Vascular endothelial growth factor induced by hypoxia may mediate hypoxia-initiated angiogenesis. Nature (1992) 18.26
Tumor cells secrete a vascular permeability factor that promotes accumulation of ascites fluid. Science (1983) 15.43
Vascular endothelial growth factor is a potential tumour angiogenesis factor in human gliomas in vivo. Nature (1992) 10.10
Pituitary follicular cells secrete a novel heparin-binding growth factor specific for vascular endothelial cells. Biochem Biophys Res Commun (1989) 7.39
The pathology of hypertensive pulmonary vascular disease; a description of six grades of structural changes in the pulmonary arteries with special reference to congenital cardiac septal defects. Circulation (1958) 7.39
Activated macrophages induce vascular proliferation. Nature (1977) 3.74
Distribution of vascular permeability factor (vascular endothelial growth factor) in tumors: concentration in tumor blood vessels. J Exp Med (1991) 3.15
Oxygen tension regulates the expression of angiogenesis factor by macrophages. Science (1983) 2.80
Coding sequence and growth regulation of the human vimentin gene. Mol Cell Biol (1986) 2.34
Tumor-secreted vascular permeability factor increases cytosolic Ca2+ and von Willebrand factor release in human endothelial cells. Am J Pathol (1991) 2.26
Binding sites for vascular endothelial growth factor are localized on endothelial cells in adult rat tissues. J Clin Invest (1992) 2.19
Rings of intermediate (100 A) filament bundles in the perinuclear region of vascular endothelial cells. Their mobilization by colcemid and mitosis. J Cell Biol (1976) 2.18
Primary pulmonary hypertension. Vascular structure, morphometry, and responsiveness to vasodilator agents. Circulation (1989) 2.16
Expression of vascular permeability factor/vascular endothelial growth factor in normal rat tissues. Am J Physiol (1993) 1.93
A working formulation for the standardization of nomenclature in the diagnosis of heart and lung rejection: Lung Rejection Study Group. The International Society for Heart Transplantation. J Heart Transplant (1991) 1.87
The histopathology of 36 cases of plexogenic pulmonary arteriopathy. Histopathology (1990) 1.85
Biosynthesis of von Willebrand protein by human endothelial cells. Identification of a large precursor polypeptide chain. J Biol Chem (1983) 1.77
Primary pulmonary hypertension: a histopathologic study of 80 cases. Mayo Clin Proc (1985) 1.57
Electron microscopy of the plexiform lesion. Thorax (1979) 1.55
Progressive inflammatory and structural changes in the pulmonary vasculature of monocrotaline-treated rats. Microvasc Res (1989) 1.23
Development of pulmonary arterial changes in rats fed Crotalaria spectabilis. Am J Pathol (1979) 1.21
The structure and significance of pulmonary plexiform structures. Am J Pathol (1960) 1.20
Immunohistochemical detection of factor VIII/von Willebrand factor in hyperplastic endothelial cells in glioblastoma multiforme and mixed glioma-sarcoma. J Neuropathol Exp Neurol (1982) 1.18
AP-1/jun binding sites mediate serum inducibility of the human vimentin promoter. Nucleic Acids Res (1989) 1.16
What is the role of endothelial cells in angiogenesis? Lab Invest (1984) 1.11
The pathology of the early and late stages of primary pulmonary hypertension. Br Heart J (1987) 1.07
The biology of malignant gliomas--a comprehensive survey. Clin Neuropathol (1984) 1.06
Comparison of primary plexogenic arteriopathy in adults and children. A morphometric study in 40 patients. Br Heart J (1985) 1.02
Repeated Escherichia coli endotoxin-induced pulmonary inflammation causes chronic pulmonary hypertension in sheep. Structural and functional changes. Lab Invest (1986) 0.96
1992 Mack Forster Award Lecture. Review. Regulation of angiogenesis in vitro. Eur J Clin Invest (1992) 0.96
Inflammation and models of chronic pulmonary hypertension. Am Rev Respir Dis (1987) 0.94
Sequence of structural changes and elastin peptide release during vascular remodelling in sheep with chronic pulmonary hypertension induced by air embolization. Am J Pathol (1991) 0.93
Interleukin 1 bioactivity in the lungs of rats with monocrotaline-induced pulmonary hypertension. Proc Soc Exp Biol Med (1988) 0.91
Case records of the Massachusetts General Hospital. Weekly clinicopathological exercises. Case 37-1992. A 68-year-old woman with rheumatoid arthritis and pulmonary hypertension. N Engl J Med (1992) 0.89
Specificity of pulmonary vascular lesions in primary pulmonary hypertension. A reappraisal. Respiration (1987) 0.88
Granulocyte depletion attenuates sustained pulmonary hypertension and increased pulmonary vasoreactivity caused by continuous air embolization in sheep. Am Rev Respir Dis (1990) 0.87
Pulmonary hypertension induced by repeated pulmonary inflammation in the rat. J Appl Physiol Respir Environ Exerc Physiol (1981) 0.87
SCHISTOSOMAL PULMONARY ARTERIAL HYPERTENSION IN EAST AFRICA. Br Heart J (1964) 0.86
The ultrastructure of the various forms of pulmonary arterial intimal fibrosis. Virchows Arch A Pathol Anat Histol (1979) 0.85
The pathology of primary pulmonary hypertension. Mod Pathol (1991) 0.85
Release of von Willebrand factor antigen (vWF:Ag) and eicosanoids during acute injury to the isolated rat lung. Am Rev Respir Dis (1992) 0.84
A comparison of continuous intravenous epoprostenol (prostacyclin) with conventional therapy for primary pulmonary hypertension. N Engl J Med (1996) 8.02
Effects of the dual endothelin-receptor antagonist bosentan in patients with pulmonary hypertension: a randomised placebo-controlled study. Lancet (2001) 6.88
Inhibition of VEGF receptors causes lung cell apoptosis and emphysema. J Clin Invest (2000) 5.26
Endothelial cell death and decreased expression of vascular endothelial growth factor and vascular endothelial growth factor receptor 2 in emphysema. Am J Respir Crit Care Med (2001) 3.92
Inhibition of the VEGF receptor 2 combined with chronic hypoxia causes cell death-dependent pulmonary endothelial cell proliferation and severe pulmonary hypertension. FASEB J (2001) 3.20
Survival with first-line bosentan in patients with primary pulmonary hypertension. Eur Respir J (2005) 2.83
Autoimmunity and pulmonary hypertension: a perspective. Eur Respir J (2005) 2.82
Inhibition of angiogenesis decreases alveolarization in the developing rat lung. Am J Physiol Lung Cell Mol Physiol (2000) 2.73
Monoclonal endothelial cell proliferation is present in primary but not secondary pulmonary hypertension. J Clin Invest (1998) 2.54
Plasma and lipids from stored packed red blood cells cause acute lung injury in an animal model. J Clin Invest (1998) 2.37
Increased gene expression for VEGF and the VEGF receptors KDR/Flk and Flt in lungs exposed to acute or to chronic hypoxia. Modulation of gene expression by nitric oxide. J Clin Invest (1995) 2.30
Changes in gene expression in the intact human heart. Downregulation of alpha-myosin heavy chain in hypertrophied, failing ventricular myocardium. J Clin Invest (1997) 2.29
Expression of angiogenesis-related molecules in plexiform lesions in severe pulmonary hypertension: evidence for a process of disordered angiogenesis. J Pathol (2001) 2.24
Prostacyclin synthase expression is decreased in lungs from patients with severe pulmonary hypertension. Am J Respir Crit Care Med (1999) 2.21
Effects of long-term infusion of prostacyclin (epoprostenol) on echocardiographic measures of right ventricular structure and function in primary pulmonary hypertension. Primary Pulmonary Hypertension Study Group. Circulation (1997) 2.03
Gene expression patterns in the lungs of patients with primary pulmonary hypertension: a gene microarray analysis. Circ Res (2001) 2.00
Platelet-activating factor mediates hemodynamic changes and lung injury in endotoxin-treated rats. J Clin Invest (1987) 1.96
Microsatellite instability of endothelial cell growth and apoptosis genes within plexiform lesions in primary pulmonary hypertension. Circ Res (2001) 1.75
Three-dimensional reconstruction of pulmonary arteries in plexiform pulmonary hypertension using cell-specific markers. Evidence for a dynamic and heterogeneous process of pulmonary endothelial cell growth. Am J Pathol (1999) 1.63
Elevated levels of leukotriene C4 in bronchoalveolar lavage fluid from atopic asthmatics after endobronchial allergen challenge. Am Rev Respir Dis (1990) 1.62
Hypoxia inducible factor-1α in human emphysema lung tissue. Eur Respir J (2010) 1.62
Proactive integrated care improves quality of life in patients with COPD. Eur Respir J (2009) 1.61
Pulmonary prostacyclin synthase overexpression in transgenic mice protects against development of hypoxic pulmonary hypertension. J Clin Invest (1999) 1.59
Nonimmunological production of leukotrienes induced by platelet-activating factor. Science (1982) 1.58
In vitro release of vascular endothelial growth factor during platelet aggregation. Am J Physiol (1998) 1.54
Hypothyroidism and primary pulmonary hypertension: an autoimmune pathogenetic link? Ann Intern Med (1993) 1.51
Smooth muscle-mediated connective tissue remodeling in pulmonary hypertension. Science (1987) 1.47
Pathogenesis and evolution of plexiform lesions in pulmonary hypertension associated with scleroderma and human immunodeficiency virus infection. Hum Pathol (1997) 1.46
Generation of oxidative stress contributes to the development of pulmonary hypertension induced by hypoxia. J Appl Physiol (1985) (2001) 1.44
Severe pulmonary hypertension and arterial adventitial changes in newborn calves at 4,300 m. J Appl Physiol (1985) (1987) 1.40
Observations on the biology and control of the chewing louse (Bovicola limbata) of Angora goats in Great Britain. Vet Rec (2001) 1.39
HOX genes in human lung: altered expression in primary pulmonary hypertension and emphysema. Am J Pathol (2001) 1.29
The pathobiology of pulmonary hypertension. Endothelium. Clin Chest Med (2001) 1.27
Pulmonary hypertension and inflammation. J Lab Clin Med (1998) 1.25
The pressure-overloaded right ventricle in pulmonary hypertension. Chest (1998) 1.24
5-Lipoxygenase and 5-lipoxygenase activating protein (FLAP) immunoreactivity in lungs from patients with primary pulmonary hypertension. Am J Respir Crit Care Med (1998) 1.18
Prostacyclin receptor-dependent modulation of pulmonary vascular remodeling. Am J Respir Crit Care Med (2001) 1.16
Coagulation and fibrinolytic profiles in patients with severe pulmonary hypertension. Chest (1996) 1.14
Prostaglandins induce vascular endothelial growth factor in a human monocytic cell line and rat lungs via cAMP. Am J Respir Cell Mol Biol (1997) 1.13
Leukotriene C4 and D4 in neonates with hypoxemia and pulmonary hypertension. N Engl J Med (1983) 1.11
PAF antagonists inhibit pulmonary vascular remodeling induced by hypobaric hypoxia in rats. J Appl Physiol (1985) (1992) 1.10
Measurement of peptidoleukotrienes in biological fluids. J Appl Physiol (1985) (1990) 1.08
Vasopressin-induced pulmonary vasodilation in rats. Am J Physiol (1989) 1.07
Alveolar inflammation and arachidonate metabolism in monocrotaline-induced pulmonary hypertension. Am J Physiol (1985) 1.06
Analysis of 6-keto PGF1 alpha, 5-HETE, and LTC4 in rat lung: comparison of GM/MS, RIA, and EIA. Prostaglandins (1986) 1.03
Monoclonal endothelial cells in appetite suppressant-associated pulmonary hypertension. Am J Respir Crit Care Med (1998) 1.00
Leukotoxin, 9,10-epoxy-12-octadecenoate causes edematous lung injury via activation of vascular nitric oxide synthase. Am J Physiol (1995) 1.00
Release of vasodilator prostaglandin, PGI2, from isolated rat lung during vasoconstriction. Circ Res (1981) 0.97
Magnesium toxicity as a cause of hypotension and hypoventilation. Occurrence in patients with normal renal function. Arch Intern Med (1985) 0.93
Decreased pulmonary vasoreactivity in an animal model of chronic Pseudomonas pneumonia. Am Rev Respir Dis (1990) 0.93
PAF antagonists: different effects on platelets, neutrophils, guinea pig ileum and PAF-induced vasodilation in isolated rat lung. Prostaglandins (1986) 0.92
Cellular adaptation during chronic neonatal hypoxic pulmonary hypertension. Am J Physiol (1991) 0.92
Hyperuricemia in severe pulmonary hypertension. Chest (2000) 0.92
Effects of hypoxia on density of beta-adrenergic receptors. J Appl Physiol Respir Environ Exerc Physiol (1981) 0.92
Decreased arterial wall prostaglandin production in neonatal calves with severe chronic pulmonary hypertension. Am J Respir Cell Mol Biol (1989) 0.91
Importance of angiotensin-converting enzyme in pulmonary hypertension. Cardiology (1995) 0.91
Endothelin-1 receptor antagonists prevent the development of pulmonary emphysema in rats. Eur Respir J (2009) 0.91
Vascular remodeling in neonatal pulmonary hypertension. Role of the smooth muscle cell. Chest (1988) 0.91
Altering hydrodynamic variables influences PGI2 production by isolated lungs and endothelial cells. J Appl Physiol Respir Environ Exerc Physiol (1984) 0.91
Endotoxin-induced lung injury in rats: role of eicosanoids. J Appl Physiol (1985) (1989) 0.91
Rapid onset of hypoxic vasoconstriction in isolated lungs. J Appl Physiol (1985) (1992) 0.90
Insulin-like growth factor I and pulmonary hypertension induced by continuous air embolization in sheep. Am J Respir Cell Mol Biol (1992) 0.90
Primary pulmonary hypertension, Castleman's disease and human herpesvirus-8. Eur Respir J (2003) 0.90
Inflammatory cells and eicosanoid mediators in subjects with late asthmatic responses and increases in airway responsiveness. J Allergy Clin Immunol (1992) 0.89
Leukotoxin, 9,10-epoxy-12-octadecenoate causes pulmonary vasodilation in rats. Am J Physiol (1995) 0.89
Colon perforation after lung transplantation. Ann Thorac Surg (1996) 0.89
Effects of shear stress on adhesive interaction between neutrophils and cultured endothelial cells. J Appl Physiol (1985) (1987) 0.88
Ventilatory responses of hamsters and rats to hypoxia and hypercapnia. J Appl Physiol (1985) (1985) 0.88
Pulmonary vascular injury by polycations in perfused rat lungs. J Appl Physiol (1985) (1987) 0.87
Plexiform lesion in severe pulmonary hypertension: association with glomeruloid lesion. Am J Pathol (2001) 0.87
Effects of acute and chronic hypoxia on rat lung cyclooxygenase. Am J Physiol (1996) 0.87
Inactivation of leukotriene C4 in the airways and subsequent urinary leukotriene E4 excretion in normal and asthmatic subjects. Am Rev Respir Dis (1993) 0.86
Leukotriene synthesis and receptor blockers block hypoxic pulmonary vasoconstriction. J Appl Physiol Respir Environ Exerc Physiol (1984) 0.86
Insulin-like growth factor I and protein kinase C activation stimulate pulmonary artery smooth muscle cell proliferation through separate but synergistic pathways. J Cell Physiol (1990) 0.86
The electrocardiogram at rest and exercise during a simulated ascent of Mt. Everest (Operation Everest II). Am J Cardiol (1990) 0.85
Lung injury in Fischer but not Sprague-Dawley rats after short-term hyperoxia. Am J Physiol (1990) 0.85
Endothelin-1 potentiates leukotoxin-induced edematous lung injury. J Appl Physiol (1985) (1995) 0.85
Chronic propranolol treatment blunts right ventricular hypertrophy in rats at high altitude. J Appl Physiol Respir Environ Exerc Physiol (1980) 0.85
PAF antagonists inhibit monocrotaline-induced lung injury and pulmonary hypertension. J Appl Physiol (1985) (1991) 0.85
"Suicide" inactivation of prostaglandin I2 synthase: characterization of mechanism-based inactivation with isolated enzyme and endothelial cells. Arch Biochem Biophys (1995) 0.85
Surgical therapy for a complication of Kawasaki's disease. Ann Thorac Surg (1983) 0.85
Increased nitric oxide biosynthesis in leukotoxin,9,10-epoxy-12-octadecenoate injured lung. Biochem Biophys Res Commun (1995) 0.85
Enhanced growth capacity of neonatal pulmonary artery smooth muscle cells in vitro: dependence on cell size, time from birth, insulin-like growth factor I, and auto-activation of protein kinase C. J Cell Physiol (1994) 0.84
Metabolism of platelet-activating factor in isolated perfused rat lung. J Clin Invest (1987) 0.84
Diethylcarbamazine inhibits acute and chronic hypoxic pulmonary hypertension in awake rats. Am Rev Respir Dis (1985) 0.84
Release of von Willebrand factor antigen (vWF:Ag) and eicosanoids during acute injury to the isolated rat lung. Am Rev Respir Dis (1992) 0.84
Actions of lipoxygenase metabolites in isolated rat lungs. J Appl Physiol Respir Environ Exerc Physiol (1984) 0.83
Transforming growth factor-beta1 induces endothelin-1 in a bovine pulmonary artery endothelial cell line and rat lungs via cAMP. Pulm Pharmacol Ther (2000) 0.83
Cutaneous and systemic responses during primary and challenge infestations of sheep with the sheep scab mite, Psoroptes ovis. Parasite Immunol (2000) 0.83
Transmission of Lactobacillus pneumonia by a transplanted lung. Ann Thorac Surg (1994) 0.83
Right ventricular phenotypic characteristics in subjects with primary pulmonary hypertension or idiopathic dilated cardiomyopathy. J Card Fail (1999) 0.83